Markets:

Overview

News

Currencies

International

Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.420 -0.300 (-8.06%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Is Recursion Pharmaceuticals Stock a Buy? ↗

September 20, 2024

It largely depends on your investing style.

Via The Motley Fool

Looking Into Recursion Pharmaceuticals's Recent Short Interest ↗

September 16, 2024

Via Benzinga

AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week ↗

September 15, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual...

Via Talk Markets

AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th ↗

September 10, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual...

Via Talk Markets

September 07, 2024

Via Talk Markets

Topics Economy

Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals ↗

September 04, 2024

Via Benzinga

How Is The Market Feeling About Recursion Pharmaceuticals? ↗

August 23, 2024

Via Benzinga

Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone! ↗

September 05, 2024

The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug...

Via Talk Markets

Topics Economy

Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher ↗

September 03, 2024

Via Benzinga

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

September 03, 2024

Via Benzinga

Nasdaq Dips Over 2%; US Construction Spending Falls In July ↗

September 03, 2024

Via Benzinga

Recursion Pharmaceuticals Stock Is Sliding Tuesday: What's Going On? ↗

September 03, 2024

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation...

Via Benzinga

Is Recursion Pharmaceuticals a Warren Buffett Stock? ↗

August 30, 2024

Don't expect Buffett to invest in this stock tomorrow, but it has the potential to eventually be a stock he would consider.

Via The Motley Fool

Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week ↗

August 27, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030.

Via Talk Markets

The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why. ↗

August 18, 2024

Merging with a former rival will bolster its capabilities.

Via The Motley Fool

Is Recursion Pharmaceuticals Stock a Buy? ↗

August 17, 2024

We'll know a little more about the biotech's prospects in a year and a half.

Via The Motley Fool

AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD ↗

August 14, 2024

The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion...

Via Talk Markets

Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks ↗

August 13, 2024

Efficiency in core processes is set to increase substantially due to AI.

Via The Motley Fool

Topics Artificial Intelligence

Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move ↗

August 12, 2024

There isn't much to suggest these businesses are actually vulnerable.

Via The Motley Fool

Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia? ↗

August 11, 2024

The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger.

Via The Motley Fool

Topics Artificial Intelligence

AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals ↗

August 08, 2024

Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industrializing drug discovery with advanced AI technologies, boasting $850 million...

Via Benzinga

Topics Artificial Intelligence

RXRX Stock Earnings: Recursion Pharmaceuticals Meets EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

RXRX stock results show that Recursion Pharmaceuticals met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

Is Recursion Pharmaceuticals a Millionaire-Maker? ↗

August 06, 2024

It's likely to experience a lot of growth.

Via The Motley Fool

99.9% of Nvidia's $380 Million Investment Portfolio Has Been Put to Work in These 4 Artificial Intelligence (AI)-Inspired Stocks ↗

July 31, 2024

Artificial intelligence (AI) colossus Nvidia has stakes in five publicly traded companies -- four of which account for almost every cent of its AI-driven portfolio.

Via The Motley Fool

Topics Artificial Intelligence

AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD ↗

July 30, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030.

Via Talk Markets

Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip? ↗

July 27, 2024

There's a lot to like about the company using automation and artificial intelligence to improve the new drug-discovery process.

Via The Motley Fool

Topics Artificial Intelligence

25 Best Artificial Intelligence Stocks to Buy Right Now ↗

July 25, 2024

Artificial intelligence is revolutionizing industries across the board. These 25 companies span the spectrum, providing investors with a diversified basket of AI-centric equities.

Via The Motley Fool

Topics Artificial Intelligence

These 7 AI Stocks Were Major Movers On Monday/Tuesday - Here's Why ↗

July 24, 2024

This article identifies the

Via Talk Markets

Topics Artificial Intelligence

3 Millionaire-Maker Artificial Intelligence (AI) Stocks ↗

July 18, 2024

For the next stage of the AI era, companies with purposeful, practical, and highly targeted solutions stand to benefit the most.

Via The Motley Fool

Topics Artificial Intelligence

Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗

July 14, 2024

The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

Headline News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

Starting at $3.75/week.

Subscribe Today